Algert Global LLC lifted its stake in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 148.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,922 shares of the biotechnology company’s stock after buying an additional 10,702 shares during the period. Algert Global LLC owned approximately 0.09% of Enanta Pharmaceuticals worth $1,532,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Principal Financial Group Inc. raised its stake in Enanta Pharmaceuticals by 3.2% during the first quarter. Principal Financial Group Inc. now owns 113,524 shares of the biotechnology company’s stock worth $9,185,000 after acquiring an additional 3,565 shares in the last quarter. TD Asset Management Inc. raised its stake in Enanta Pharmaceuticals by 203.2% during the second quarter. TD Asset Management Inc. now owns 40,761 shares of the biotechnology company’s stock worth $4,724,000 after acquiring an additional 27,319 shares in the last quarter. First Trust Advisors LP acquired a new position in Enanta Pharmaceuticals during the second quarter worth $8,029,000. Alps Advisors Inc. raised its stake in Enanta Pharmaceuticals by 6.0% during the second quarter. Alps Advisors Inc. now owns 33,135 shares of the biotechnology company’s stock worth $3,840,000 after acquiring an additional 1,872 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Enanta Pharmaceuticals during the second quarter worth $354,000. Institutional investors and hedge funds own 85.18% of the company’s stock.
In other news, insider Tim Ocain sold 25,000 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $83.64, for a total value of $2,091,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction on Thursday, September 20th. The shares were sold at an average price of $95.32, for a total value of $396,054.60. Following the completion of the sale, the vice president now owns 4,155 shares of the company’s stock, valued at $396,054.60. The disclosure for this sale can be found here. Company insiders own 10.56% of the company’s stock.
Several research analysts have issued reports on the company. Zacks Investment Research lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Oppenheimer set a $100.00 price objective on Enanta Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, August 14th. TheStreet lowered Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, November 26th. Finally, BidaskClub upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $104.00.
Shares of NASDAQ:ENTA opened at $73.03 on Friday. Enanta Pharmaceuticals Inc has a twelve month low of $47.49 and a twelve month high of $127.77. The firm has a market capitalization of $1.48 billion, a PE ratio of 20.99 and a beta of 0.91.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, November 26th. The biotechnology company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.06. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. The company had revenue of $67.20 million during the quarter, compared to analyst estimates of $69.03 million. During the same period last year, the company posted $1.86 earnings per share. The firm’s quarterly revenue was down 11.5% compared to the same quarter last year. Sell-side analysts predict that Enanta Pharmaceuticals Inc will post 1.7 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Algert Global LLC Boosts Stake in Enanta Pharmaceuticals Inc (ENTA)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/algert-global-llc-boosts-stake-in-enanta-pharmaceuticals-inc-enta.html.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Story: Day Trading – Risk Worth the Reward?
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.